Breaking the ‘don’t eat me’ signal: in silico design of CD47-directed peptides for cancer immunotherapy
Molecular Diversity - Trang 1-17 - 2023
Tóm tắt
The leading cause of death worldwide is cancer. Although there are various therapies available to treat cancer, finding a successful one can be like searching for a needle in a haystack. Immunotherapy appears to be one of those needles in the haystack of cancer treatment. Immunotherapeutic agents enhance the immune response of the patient’s body to tumor cells. One of the immunotherapeutic targets, Cluster of Differentiation 47 (CD47), releases the "don't eat me" signal when it binds to its receptor, Signal Regulatory Protein (SIRPα). Tumor cells use this signal to circumvent the immune system, rendering it ineffective. To stop tumor cells from releasing the "don't eat me" signal, the CD47–SIRPα interaction is specifically targeted in this study. To do so, in silico peptides were designed based on the structural analysis of the interaction between two proteins using point mutations on the interacting residues with the other amino acids. The peptide library was designed and docked on SIRPα using computational tools. Later on, after analyzing the docked complex, the best of them was selected for MD simulation studies of 100 ns. Further analysis after MD studies was carried out to determine the possible potential anti-SIRPα peptides.
Tài liệu tham khảo
Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105. https://doi.org/10.1200/jco.1999.17.7.2105
Kirkwood JM, Strawderman MH, Ernstoff MS et al (2023) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 41:425–435. https://doi.org/10.1200/JCO.22.02264
Hodi FS, Oble DA, Drappatz J et al (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5:557–561. https://doi.org/10.1038/ncponc1183
Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020.
Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545–2554. https://doi.org/10.1056/NEJMoa1708566
Sarnaik AA, Hamid O, Khushalani NI et al (2021) Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol 39:2656–2666. https://doi.org/10.1200/JCO.21.00612
Hou AJ, Chen LC, Chen YY (2021) Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov 20:531–550. https://doi.org/10.1038/s41573-021-00189-2
Poschke I, Mougiakakos D, Kiessling R (2011) Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 60:1161–1171. https://doi.org/10.1007/s00262-011-1012-8
Jaiswal S, Jamieson CHM, Pang WW et al (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271–285. https://doi.org/10.1016/j.cell.2009.05.045
Dizman N, Buchbinder EI (2021) Cancer therapy targeting CD47/SIRPα. Cancers (Basel) 13:6229. https://doi.org/10.3390/cancers13246229
Hiam-Galvez KJ, Allen BM, Spitzer MH (2021) Systemic immunity in cancer. Nat Rev Cancer 21:345–359. https://doi.org/10.1038/s41568-021-00347-z
Qin S, Xu L, Yi M et al (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18:1–14. https://doi.org/10.1186/s12943-019-1091-2
Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255–262. https://doi.org/10.1038/46218
Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.x
Morotti M, Albukhari A, Alsaadi A et al (2021) Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer 124:1759–1776. https://doi.org/10.1038/s41416-021-01353-6
Nowicki A, Szenajch J, Ostrowska G et al (1996) Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 65:112–119. https://doi.org/10.1002/(SICI)1097-0215(19960103)65:1%3C112::AID-IJC19%3E3.0.CO;2-I
Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612. https://doi.org/10.1158/0008-5472.CAN-05-4005
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–265. https://doi.org/10.1002/path.1027
Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740. https://doi.org/10.1084/jem.193.6.727
Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11:130–135. https://doi.org/10.1016/S0962-8924(00)01906-1
Advani R, Flinn I, Popplewell L et al (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 379:1711–1721. https://doi.org/10.1056/NEJMoa1807315
Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (2017) The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev 276:145–164. https://doi.org/10.1111/imr.12527
Oldenborg P-A, Zheleznyak A, Fang Y-F et al (2000) Role of CD47 as a marker of self on red blood cells. Science 288:2051–2054. https://doi.org/10.1126/science.288.5473.2051
Feng R, Zhao H, Xu J, Shen C (2020) CD47: the next checkpoint target for cancer immunotherapy. Crit Rev Oncol Hematol 152:103014. https://doi.org/10.1016/j.critrevonc.2020.103014
Burger P, Hilarius-Stokman P, De Korte D et al (2012) CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood. Am J Hematol 119:5512–5521. https://doi.org/10.1182/blood-2011-10-386805
Chao MP, Jaiswal S, Weissman-Tsukamoto R et al (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2:6394–6394. https://doi.org/10.1126/scitranslmed.3001375
Mawby WJ, Holmes CH, Anstee DJ et al (1994) Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 304:525–530. https://doi.org/10.1042/bj3040525
Hatherley D, Graham SC, Turner J et al (2008) Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell 31:266–277. https://doi.org/10.1016/j.molcel.2008.05.026
Roel-Touris J, Don CG, V. Honorato R, et al (2019) Less is more: coarse-grained integrative modeling of large biomolecular assemblies with HADDOCK. J Chem Theory Comput 15:6358–6367. https://doi.org/10.1021/acs.jctc.9b00310
Dominguez C, Boelens R, Bonvin AMJJ (2003) HADDOCK: a protein−protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125:1731–1737. https://doi.org/10.1021/ja026939x
Vangone A, Rodrigues J, Xue LC et al (2017) Sense and simplicity in HADDOCK scoring: lessons from CASP-CAPRI round 1. Proteins 85:417–423. https://doi.org/10.1002/prot.25198
De Vries SJ, Van Dijk M, Bonvin AMJJ (2010) The HADDOCK web server for data-driven biomolecular docking. Nat Protoc 5:883–897. https://doi.org/10.1038/nprot.2010.32
Hornak V, Abel R, Okur A et al (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65:712–725. https://doi.org/10.1002/prot.21123
Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935. https://doi.org/10.1063/1.445869
Case DA, Cheatham TE III, Darden T et al (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668–1688. https://doi.org/10.1002/jcc.20290
van Gunsteren WF, Berendsen HJC (1977) Algorithms for macromolecular dynamics and constraint dynamics. Mol Phys 34:1311–1327. https://doi.org/10.1080/00268977700102571
Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092. https://doi.org/10.1063/1.464397
Roe DR, Cheatham TE III (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9:3084–3095. https://doi.org/10.1021/ct400341p
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38. https://doi.org/10.1016/0263-7855(96)00018-5
Reva BA, Finkelstein AV, Skolnick J (1998) What is the probability of a chance prediction of a protein structure with an rmsd of 6å. Fold Des 3:141–147. https://doi.org/10.1016/s1359-0278(98)00019-4
Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods: II: the accuracy of ranking poses generated from docking. J Comput Chem 32(5):866. https://doi.org/10.1002/jcc.21666
Huang B, Bai Z, Ye X, Zhou C, Xie X, Zhong Y, Lin K, Ma L (2021) Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. CSBJ 19:5494–5503. https://doi.org/10.1016/j.csbj.2021.09.036